TCR2 Therapeutics (TCRR) Reports Q1 Loss of $4.85
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
TCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 4:07 PM EDTInitiated Phase 1/2 clinical trial for TC-210, TCR2s lead product candidate targeting mesothelin expressing solid tumorsOn track to file an IND for TCR2s lead hematology product candidate, TC-110, in patients with CD19+ non-Hodgkin lymphomas and leukemias in 2H 2019Recent publication in Nature Communications and scientific presentations highlight advantages of the Companys TRuC-T cell platformEstablished occupancy of manufacturing suite at Cell and Gene Therapy Catapult in the UK
CAMBRIDGE, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq:... More
